Medical technology company specializing in the treatment of glaucoma with micro-invasive surgical solutions.
Glaukos Corporation is a leading medical technology and pharmaceutical company specializing in innovative treatments for ophthalmic conditions such as glaucoma, corneal disorders, and retinal diseases. At the forefront of its offerings are the iStent family of products, including iStent, iStent inject, and iStent inject W micro-bypass stents. These devices are strategically implanted during cataract surgery to enhance aqueous humor outflow, effectively treating mild-to-moderate open-angle glaucoma.
In addition to its established products, Glaukos Corporation continues to innovate with a robust pipeline that includes iStent Infinite, a revolutionary three-stent product designed for patients with refractory glaucoma. The company also develops iDose TR, an injectable implant utilizing its advanced micro-scale device platform to deliver therapeutic levels of medication directly to the eye.
Glaukos Corporation operates a global presence, distributing its products both directly and through international distributors. Its comprehensive approach to eye care solutions underscores its commitment to advancing treatment options and improving patient outcomes worldwide.
Founded in 1998 and headquartered in San Clemente, California, Glaukos Corporation remains dedicated to pioneering advancements in ophthalmic medical technology, ensuring its continued leadership in the field of eye health.